Description: Epigenomics AG is a Germany-based molecular diagnostics company focused on blood-based detection, prognosis and monitoring of cancers using deoxyribonucleic acid (DNA) methylation technology. It develops and commercializes blood-based diagnostic products across multiple cancer indications. The Company's main product is Epi proColon, a blood test for colorectal cancer screening. Along with the blood-based tests the Company offers services related to research, product development, regulatory approval and manufacturing of in-vitro diagnostic (IVD) products. It also offers Epi proLung, a blood-based test that detects the presence of lung cancer in blood plasma. The Company is present in Europe and the United States.
Home Page: www.epigenomics.com
Ziegelhäuser Landstraße 3
Heidelberg,
69120
Germany
Phone:
49 6221 64924
Officers
| Name | Title |
|---|---|
| Mr. Hansjorg Plaggemars | Member of Executive Board |
| Frederic Hilke | Investor Relations Officer |
| Dr. Noel Thomas Doheny | Chief Executive Officer of Epigenomics Inc. |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.3257 |
| Price-to-Sales TTM: | 5.0751 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 6 |